Live
- SIPB approves Rs 85,000 cr investments
- AP Assembly session: Eighth day meeting begins with question hour
- Facial recognition attendance system in TG Secretariat soon
- Nearly 6,000 contract employees whose services were regularised get relief in HC
- VIT celebrates 40th anniversary
- Bandi Sanjay reviews ‘Sampoorna Abhiyan’ in Nagaland
- A brain dead person saves four as his organs donated
- SRR students excel in various competitions
- ISRO's communication satellite launched by Musk's SpaceX
- Encouragement assured for innovation in farming
Dr Reddy’s Laboratories buys 6 OTC brands from Ducere
City-based pharmaceutical major, Dr Reddy’s Laboratories Limited, has entered the branded consumer health arena with the acquisition of six over-the-counter (OTC) brands from Ducere Pharma LLC, which manufactures, markets and distributes more than eight drugs in the US.
Hyderabad: City-based pharmaceutical major, Dr Reddy’s Laboratories Limited, has entered the branded consumer health arena with the acquisition of six over-the-counter (OTC) brands from Ducere Pharma LLC, which manufactures, markets and distributes more than eight drugs in the US.
The brands, acquired for an undisclosed amount, include Doan’s, Bufferin, Nupercainal ointment, Cruex nail gel, comtrex and myoflex, which are indicated for the treatment of cough-and-cold, pain and dermatology issues.
“These legacy products enjoy strong brand equity built over several decades. We are extremely excited to be entering the branded consumer health arena through these brands and embarking upon the next avenue of growth for our OTC business in the US,” said Alok Sonig, Executive Vice-President and Head of Dr Reddy’s in the US.
According to him, Dr Reddy’s will build upon the sales and marketing efforts for these brands and continue to focus on their expansion into existing and new market channels. Dr Reddy’s Laboratories’ scrip ended the trade at Rs 3,052.95 on the BSE on Wednesday, up 0.92 per cent, over the previous close of Rs 3025.25 per share.
